Urological cancer experts to examine latest treatment, research findings at 27th Annual EAU Congress

International urological cancer experts will examine the latest treatment and research findings at the 27^th Annual EAU Congress in Paris, France on 24-28 February 2012. From innovative diagnostic procedures, novel treatment options for bladder and prostate cancers, minimal invasive surgery to combination therapies for kidney cancer, around 10,000 urological and cancer specialists will gather to present and discuss current trends that impact the treatment of urological diseases.

"With the outcomes of the latest research and clinical studies in prostate, bladder, kidney and other urological diseases, we have an international platform to examine contemporary medical and surgical practices. New research results that will mean benefits to our patients will be discussed in a multidisciplinary setting, while at the same time putting emphasis on how these developments will impact on the practice of urology specialists," said the EAU Scientific Office in a statement. 

Live surgeries broadcasted from three sites located in Paris (FR), Mannheim in Germany and Aalst in Belgium will be presented on February 25 during the meeting of the EAU Section of Uro-Technology (ESUT), including a Natural Orifice Transluminal Endoscopic Surgery

(NOTES)/ nephrectomy procedure. It will be the first time the ESUT will transmit live surgery on NOTES involving a kidney donor during an annual EAU congress.

For media representatives, a press briefing is scheduled on Saturday, 25 February 2012 at the Le Palais des Congrès from 12.00 to 13.15 hrs. A range of topics including the latest updates in prostate cancer diagnostics, new therapies for bladder cancer, robot-assisted surgery, and issues in overactive bladder, among others, will be discussed in an open forum with both the general and specialised press.

One of the invited experts, Prof. Jelle Barentz, Nijmegen (NL) will speak on a novel way of diagnosing prostate cancer (PCa) using functional multi-modality MR (magnetic resonance) imaging. Confirming PCa diagnosis is one of the challenges for urologists and Barentz's team provides insights into how this technique can be of great value to patients.

The EAU Executives will also discuss with the press the current trends and newest data on minimal invasive therapies, overactive bladder, advanced metastatic PCa, bladder and kidney cancers. EAU Secretary General Prof. Per-Anders Abrahamsson (SE) will lead the panellists.